The Food and Drug Administration Friday authorized using the monoclonal antibody therapy REGEN-COV for prevention in certain children and adults who are not fully vaccinated against COVID-19 or not expected to mount an adequate immune response to vaccination. 

FDA also authorized administering baricitinib (Olumiant) by itself to treat COVID-19 in hospitalized patients age 2 and older who require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation. The emergency use authorization previously required administering baricitinib with remdesivir (Veklury). 
 

Related News Articles

Headline
Commenting on a forthcoming Centers for Medicare & Medicaid Services’ rule requiring COVID-19 vaccinations for workers in most health care settings…
Chairperson's File
On this episode, I discuss emergency preparedness, caregiver resiliency and health equity — all through the lens of the COVID-19 pandemic — with Fritz Francois…
Headline
The Centers for Medicare & Medicaid Services today announced that the agency will pay for Medicare beneficiaries’ booster doses, without cost sharing…
Headline
AHA today urged the Office of the United States Trade Representative to extend the current Section 301 tariff exemptions for certain medical devices to ensure…
Headline
The Centers for Disease Control and Prevention early Friday morning opted for a broad endorsement of Pfizer COVID-19 vaccine booster shots, issuing interim…
Headline
The AHA today urged the Health Resources and Services Administration to quickly distribute the $17 billion in Phase 4 provider relief funds and $8.5 billion in…